Lupin gets EIR from USFDA for Pithampur unit- 1 manufacturing facility

09 Jan 2025 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Pithampur Unit-1 manufacturing facility that manufactures both APIs and finished products. The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024.  

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2103.30 -8.70 (-0.41%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×